Toralgen develops a proprietary poly-bile nanoparticle platform that enables effective oral delivery of biologics, replacing injections with a simple pill that protects drugs through the gastrointestinal tract. This technology enhances drug bioavailability and uptake, addressing the challenges of oral administration for treatments of metabolic and autoimmune diseases.
Funding
$8.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many biologic drugs require administration via injection due to poor oral bioavailability, leading to patient discomfort, inconvenience, and adherence challenges. Oral delivery of biologics is hindered by degradation in the gastrointestinal tract and limited absorption across the intestinal wall.
Solution
Toralgen is developing a poly-bile acid nanoparticle platform to enable oral delivery of biologics and other therapeutic modalities. The nanoparticles protect encapsulated drugs from degradation in the stomach and enhance absorption in the intestines through the enterohepatic pathway. This approach aims to replace injections with orally administered pills, improving patient compliance and drug efficacy. The platform is capable of encapsulating small molecules, peptides, proteins, and monoclonal antibodies.
Target Audience
The primary target audience includes pharmaceutical companies developing biologics and other therapeutics for metabolic and autoimmune diseases, as well as patients who require these treatments.
Features
- Poly-bile acid nanoparticles composed of naturally occurring bile acids for enhanced biocompatibility
- Protection of encapsulated drugs from degradation in the gastrointestinal tract
- Enhanced drug uptake through the enterohepatic pathway
- Demonstrated Cmax of over 35% in rodent PK studies for small molecules
- Drug loading capacity of greater than 10% wt/wt for biologics, including peptides
- Potential for oral delivery of antigens and immunomodulators